Morgan Stanley’s 5 Stock Picks for 2023

2. Zoetis Inc. (NYSE:ZTS)

Share Price Upside: 57%
Number of Hedge Fund Holders: 65

In the healthcare sector, Zoetis Inc. (NYSE:ZTS) discovers, develops and commercializes animal health medicines, vaccines and diagnostic products. It mostly deals with products across species, including livestock, swine, poultry, fish, sheep, etc.

Morgan Stanley analyst Erin Wright remains upbeat about Zoetis Inc. (NYSE:ZTS); up by about 7% for the year, aligning with the 85 S&P 500 gain. The analysts maintain a Buy rating with a $248 price target, implying a 57% upside potential.

Out of the 910 hedge funds that Insider Monkey surveyed, 65 had invested in the company’s shares by June 2023. The hedge fund with the prominent stake in Zoetis Inc. (NYSE:ZTS) was Bailard Inc., run by Thomas Bailard, with a $9.67 million holding.

Follow Zoetis Inc. (NYSE:ZTS)

[/company-follow-email]